Pathology of pp32 in Breast Cancer
Abstract
DFDRJRKJFKRJBreast cancers differ from benign breast epithelium through prominent expression of oncogenic pp32 gene family members. Whereas benign breast epithelium predominantly expresses pp32, a tumor suppressor, breast cancers express pp32r1 and pp32r2, which are oncogenic. The study purpose is to confirm and extend these preliminary results, to develop practical means to assay pp32 gene family members in clinical samples, and to determine the clinical significance of their presence in pre-invasive breast disease. The approved proposal encompassed four broad tasks: 1 characterization of the pp32 expression phenotype of a larger sample of 40 breast cancers; 2 development of a practical assay for altered pp32 transcripts in archival tissue; 3 determination of the association of specific pp32 variants in laser capture microdissected DCIS with invasion and with high-grade comedo DCTS; and 4 application of the results in a retrospective study (if 3 shows meaningful correlations) to a population of patients with follow-up. During the reporting period, we developed quantitative assays pp32, pp32r1, and pp32 mRNA copy number in breast cancer cell lines and in normal tissues demonstrating that the representation of pp32r1 and pp32r2 is relatively low in comparison to pp32. This assay is now ready for application to clinical samples.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2001
- Accession Number
- ADA405528
Entities
People
- Gary R. Pasternack
Organizations
- Johns Hopkins University